Abstract
Withania somnifera commonly known as Ashwagandha in India is used in many herbal formulations to treat various cardiovascular diseases. The key metabolite of this plant, Withaferin A was analyzed for its molecular mechanism through docking studies on different targets of cardiovascular disease. Six receptor proteins associated with cardiovascular disease were selected and interaction studies were performed with Withaferin A using AutoDock Vina. CORINA was used to model the small molecules and HBAT to compute the hydrogen bonding. Among the six targets, β1- adrenergic receptors, HMG-CoA and Angiotensinogen-converting enzyme showed significant interaction with Withaferin A. Pharmacophore modeling was done using PharmaGist to understand the pharmacophoric potential of Withaferin A. Clustering of Withaferin A with different existing drug molecules for cardiovascular disease was performed with ChemMine based on structural similarity and physicochemical properties. The ability of natural active component, Withaferin A to interact with different receptors associated with cardiovascular disease was elucidated with various modeling techniques. These studies conclusively revealed Withaferin A as a potent lead compound against multiple targets associated with cardiovascular disease.
Keywords: Docking, Ashwagandha, herbal, beta receptor.
Current Computer-Aided Drug Design
Title:Interaction studies of Withania somnifera’s key metabolite Withaferin A with different receptors associated with cardiovascular disease
Volume: 11 Issue: 3
Author(s): Rekha Ravindran, Nitika Sharma, Sujata Roy, Ashoke R. Thakur, Subhadra Ganesh, Sriram Kumar, Jamuna Devi and Johanna Rajkumar
Affiliation:
Keywords: Docking, Ashwagandha, herbal, beta receptor.
Abstract: Withania somnifera commonly known as Ashwagandha in India is used in many herbal formulations to treat various cardiovascular diseases. The key metabolite of this plant, Withaferin A was analyzed for its molecular mechanism through docking studies on different targets of cardiovascular disease. Six receptor proteins associated with cardiovascular disease were selected and interaction studies were performed with Withaferin A using AutoDock Vina. CORINA was used to model the small molecules and HBAT to compute the hydrogen bonding. Among the six targets, β1- adrenergic receptors, HMG-CoA and Angiotensinogen-converting enzyme showed significant interaction with Withaferin A. Pharmacophore modeling was done using PharmaGist to understand the pharmacophoric potential of Withaferin A. Clustering of Withaferin A with different existing drug molecules for cardiovascular disease was performed with ChemMine based on structural similarity and physicochemical properties. The ability of natural active component, Withaferin A to interact with different receptors associated with cardiovascular disease was elucidated with various modeling techniques. These studies conclusively revealed Withaferin A as a potent lead compound against multiple targets associated with cardiovascular disease.
Export Options
About this article
Cite this article as:
Ravindran Rekha, Sharma Nitika, Roy Sujata, Thakur R. Ashoke, Ganesh Subhadra, Kumar Sriram, Devi Jamuna and Rajkumar Johanna, Interaction studies of Withania somnifera’s key metabolite Withaferin A with different receptors associated with cardiovascular disease, Current Computer-Aided Drug Design 2015; 11 (3) . https://dx.doi.org/10.2174/1573409912666151106115848
DOI https://dx.doi.org/10.2174/1573409912666151106115848 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents on Polymeric Scaffolds for Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) Bradykinin Antagonists as Anti-Cancer Agents
Current Pharmaceutical Design Sleep Disordered Breathing: Alternatives to CPAP Therapy
Current Respiratory Medicine Reviews Modulators of Ion Channels Activated by Hypotonic Swelling in Cardiomyocytes: New Perspectives for Pharmacological Treatment of Life-Threatening Arrhythmias
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Role of Immunosuppressive Medications in the Pathogenesis of Hypertension and Efficacy and Safety of Antihypertensive Agents in Kidney Transplant Recipients
Current Medicinal Chemistry Life-history Constraints on the Mechanisms that Control the Rate of ROS Production
Current Genomics Fungal Bioactive Compounds in Pharmaceutical Research and Development
Current Bioactive Compounds Systems Biology Research into Cardiovascular Disease: Contributions of Lipidomics-based Approaches to Biomarker Discovery
Current Drug Discovery Technologies Piperine: Medicinal, Analytical and Therapeutics perspective
Current Bioactive Compounds Impact of Renin-Angiotensin System in Hepatocellular Carcinoma
Current Cancer Drug Targets Cross-Talking Between PPAR and WNT Signaling and its Regulation in Mesenchymal Stem Cell Differentiation
Current Stem Cell Research & Therapy Editorial: Thematic Issue-Topic–Diabetic Cardiovascular Disease–An Unmet Medical Need: Emerging Targets and Therapies-Introduction to the Special Issue
Cardiovascular & Hematological Agents in Medicinal Chemistry Are Calcium Channel Blockers First-Line Drugs for the Treatment of Hypertension and Cardiovascular Disease?
Current Hypertension Reviews T-type Calcium Channels in Health and Disease
Current Medicinal Chemistry Reconstituted High Density Lipoprotein-Based Nanoparticles: an Overview of Applications in Regenerative Medicine, Preparation, Evaluation and Future Trends
Current Pharmaceutical Design Lysosomal Storage Diseases and the Blood-Brain Barrier
Current Pharmaceutical Design Regulation of Blood Flow by Prostaglandins
Current Vascular Pharmacology Beta-Blockers: Effects on Bone Mineral Density and Fracture Risk
Current Rheumatology Reviews The Pleiotropic Effects of Inducible Nitric Oxide Synthase (iNOS) on the Physiology and Pathology of Penile Erection
Current Pharmaceutical Design The Hypothalamic-Neurohypophyseal System: Current and Future Treatment of Vasopressin and Oxytocyn Related Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery